Volume | 567,043 |
|
|||||
News | - | ||||||
Day High | 5.95 | Low High |
|||||
Day Low | 5.16 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Black Diamond Therapeutics Inc | BDTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
5.16 | 5.16 | 5.95 | 5.89 | 5.11 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
6,263 | 567,043 | US$ 5.58 | US$ 3,162,850 | - | 1.43 - 6.85 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:46:11 | 40 | US$ 5.87 | USD |
Black Diamond Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
304.1M | 51.72M | - | 0 | -82.44M | -1.59 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Black Diamond Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BDTX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 5.17 | 5.95 | 4.87 | 5.09 | 369,309 | 0.6103 | 11.80% |
1 Month | 5.21 | 6.21 | 4.56 | 5.25 | 493,207 | 0.5703 | 10.95% |
3 Months | 4.21 | 6.21 | 3.57 | 4.85 | 607,759 | 1.57 | 37.30% |
6 Months | 1.92 | 6.21 | 1.62 | 3.76 | 542,712 | 3.86 | 201.06% |
1 Year | 1.50 | 6.85 | 1.43 | 5.21 | 1,432,606 | 4.28 | 285.35% |
3 Years | 26.62 | 29.02 | 1.18 | 5.95 | 688,344 | -20.84 | -78.29% |
5 Years | 33.00 | 46.25 | 1.18 | 9.42 | 566,016 | -27.22 | -82.48% |
Black Diamond Therapeutics Description
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under pipeline are BDTX-189 and BDTX-1535. |